"We believe these investigational oral SERDs
could one day redefine the standard of care for hormone receptor-positive breast cancer."
Scientists at Seragon have developed next-generation selective estrogen receptor degraders (SERDs).
Seragon s lead product candidate, ARN-810, is a next-generation SERD that is currently in Phase I clinical trials for patients who have hormone receptor-positive breast cancer and have failed current hormonal agents.
SERDS (server relational data system) is a multi user DBMS which was developed starting from RDS.
As such, its main task consists of scheduling the requests received from SNC for execution by SERDS and of passing back the corresponding answers.
The target, based in San Diego, California, specialises in the development of selective estrogen receptor degraders (SERDs
) for hormone receptor-driven cancers.